PubMed Health⌕ Search

Biomedical subjects

F Heinrich

Publications and source records attributed to F Heinrich.

At least 19 recordsLinked to original sources
PubMed1992

Evaluation of plasma D-dimer in the diagnosis and in the course of fibrinolytic therapy of deep vein thrombosis and pulmonary embolism.

Blood samples were obtained from patients with deep venous thrombosis (DVT) or pulmonary embolism (PE) after angiographic confirmation as well as during fibrinolytic therapy with streptokinase. Plasma cross-linked fibrin degradation products were measured by a quantitative enzyme-linked immunoassay that recognizes the D-Dimer epitope. 24 patients with PE showed elevated D-Dimer levels (median; 25%-, 75%-quartile) (3,250 ng/ml; 1,270 ng/ml, 6,940 ng/ml) as well as 38 patients presenting with DVT (2,330 ng/ml; 1,760 ng/ml, 3,980 ng/ml). The sensitivity for the diagnosis of PE was 92%, for diagnosis of DVT 89% resp. 100%, depending on the cut-off limit. The D-Dimer level showed a correlation (r = 0.64) to the angiographically documented severity of PE quantified by the Miller's score, in contrast to DVT, where no such correlation could be found. During fibrinolytic therapy median levels rose from 3,020 ng/ml to 63,000 ng/ml within 8 hours and then fell within 6 days to 2,930 ng/ml. 10 patients with PE showed a good correlation (r = 0.72) between the reduction of Miller's score within 72 hours and D-Dimer 24 hours after the onset of therapy. In 17 patients with fibrinolytic treatment of DVT no correlation between D-Dimer and clot lysis could be found. These findings indicate that D-Dimer can provide additional information in the diagnostic procedure of suspected PE. During fibrinolytic therapy of PE with streptokinase, D-Dimer could serve as an early prognostic parameter of successful thrombolysis.

Biomarkers↗
PubMed1990

[New developments and findings in the field of opiates, opioids, opiate receptors and complete and partial opiate antagonists].

The historical development of the application of opiates is reviewed. After the detection and localization of opiate receptors in 1973, the clinical application of these substances has been scientifically and systematically developed. The function of the opiate system, the theory of opiate receptors, the opioid peptides, substance P as well as different opiates and analgesics are discussed in detail. The international trend in recent research efforts is aimed at finding a kappa-receptor specific opioid. The aim is to develop a selectively analgesic-acting opioid without respiratory depressant and addictive effects and without cardiovascular and excitative side-effects. Although major progress has been made in synthesizing the partial opiate agonist and opiate antagonist nalbuphine ++ (nubain), it has not yet been possible to develop a drug completely corresponding to ideal concepts.

Endorphins↗
PubMed1990

[Initial clinical experiences with the combination of catheter peridural anesthesia and general anesthesia].

From the international point of view, the combination of epidural anaesthesia and general anaesthesia is still under controversial discussion. We analysed 35 cases which were treated by this anaesthesiological method between 1987 and 1988. The catheter epidural anaesthesia showed advantages mainly in the postoperative course. Analgesia was nearly complete. Respiratory depression which is caused by systemically applied opiates was not observed. Sympathicolysis led to a good perfusion of the legs and enabled a quick overcoming postoperative intestinal atonia. During the operation above all the does of drugs with respiratory depressant effect could be diminished. The complications observed mainly included the cardiovascular system and consisted in decreases of arterial blood pressure and heart rate. Side-effects can be reduced to the greatest possible extent by correct application of this procedure.

Adult↗
PubMed1987

[Is cardiac involvement found also in European erythema migrans borreliosis?].

During an infection with Borrelia burgdorferi two men (aged 59 and 61 years, respectively) developed long-lasting cardiac arrhythmias which proved difficult to treat (tachycardias; in one patient due to atrial fibrillation, and also nodal arrhythmias). The cardiac signs completely regressed after specific antibiotic treatment, supporting the view that the cardiac involvement was due to borrelia infection, as is known to have occurred with Lyme disease reported from the USA.

Arrhythmias, Cardiac↗
PubMed1987

A double-blind dose response comparison of oral enoximone and placebo for congestive heart failure.

Enoximone (MDL 17,043), a newly synthesized imidazole derivate, has been shown to possess both positive inotropic and vasodilating properties. Sixteen patients with congestive heart failure were allocated to receive either enoximone, 50, 100 or 150 mg, or placebo, each given 3 times daily for 4 weeks, to investigate the dose-related efficacy and tolerability of oral enoximone. Symptom-limited exercise capacity improved in 5 of 10 patients in the enoximone group. The ejection fraction increased from 28% to 36% after 4 weeks, to 36% after 8 weeks and to 35% after 12 weeks in the enoximone group. Exercise duration and ejection fraction did not change in the patients in the placebo group. With enoximone, heart rate, blood pressure, Holter monitoring and laboratory tests showed no significant drug-related changes. The addition of oral enoximone to existing therapy with digitalis and diuretics may improve the clinical condition and left ventricular function in patients with congestive heart failure. Enoximone shows clinical efficacy at dosages of 50 mg and 100 mg 3 times daily. With the higher dosage, unwanted side effects increased but efficacy did not. Enoximone did not increase ventricular ectopy in the doses given.

Administration, Oral↗
PubMed1984

[Naftidrofuryl in arterial occlusive disease. Controlled multicenter double-blind study with oral administration].

The efficacy of naftidrofuryl ( Dusodril ) for treatment of stage II arterial occlusive disease was evaluated in a controlled multi-centre study in a total of 104 out-patients with angiographically documented localization of occlusion. The therapeutic effect was assessed over three months by measurements of walking distance using standardized treadmill conditions. Further parameters were venoocclusive plethysmography and Doppler ultrasonography measurement of pressures. The complaint-free walking distance increased significantly during daily application of 600 mg naftidrofuryl orally (n = 54) during the 12-week assessment period when compared to the placebo group (n = 50). Taking the intraindividual variability of 17.2 m in assessment of walking distance into account, the increase of painless walking of 93 m after treatment for 12 weeks in the active-drug group is considered the result of treatment-induced increased performance.

Administration, Oral↗
PubMed1984

Naftidrofuryl in chronic arterial disease. Results of a controlled multicenter study.

In a double blind, randomized multicenter study naftidrofuryl, a vasoactive substance, was compared with placebo in the treatment of 104 patients with chronic arterial occlusive disease. After a run-in period of four weeks the patients received either naftidrofuryl (600 mg daily) or placebo over 12 weeks. The pain-free and the total walking distances improved significantly in both groups. However, the difference in the improvement of the pain-free walking distance was significant (p less than 0.02) in favour of naftidrofuryl. There also was a difference in the improvement of the total walking distance in favour of naftidrofuryl which was not significant. The results indicate that naftidrofuryl has a beneficial effect on the symptoms and lengthens the painfree walking distance in patients with arterial occlusive disease.

Adult↗
PubMed1981

[Prevention of venous thrombosis in recent ischaemic cerebrovascular accident: double-blind study with heparin-dihydroergotamine (author's transl)].

In a randomised, double-blind study 5,000 IU heparin-dihydroergotamine mesylate (Dihydergot) or placebo were administered over 14 days to 107 patients with recent ischaemic cerebrovascular accident. The patients were studied daily for recent venous thrombosis in the legs by means of the 125I-fibrinogen test. Thirteen patients died before venous thrombosis had been demonstrated, 13 others were excluded by other causes. Of the 41 patients in the placebo group 23 developed venous thrombosis, but only 11 of the 40 drug-treated patients. Bilateral venous thrombosis occurred in six patients on the placebo and one patient on the drug. Univariate analysis indicated that heart failure, reduction of muscle tone, muscular power and level of consciousness favoured thrombosis. Multivariate analysis further indicated that both bed-rest of several days before start of the prophylactic treatment and extreme obesity favoured thrombosis. The relative thrombosis risk increased by a factor of 15.2 when prophylactic measures were omitted. Death rate in the treated group ws 17.4%, in the placebo group 28.0%. These results indicate that a prophylactic regimen of the type described is a practicable and effective measure after recent ischaemic cerebrovascular accident.

Aged↗